share_log

Laidlaw & Co. Initiates Coverage On SILO Pharma With Buy Rating, Announces Price Target of $10

Benzinga ·  Aug 28, 2023 16:51

Laidlaw & Co. analyst Yale Jen initiates coverage on SILO Pharma (NASDAQ:SILO) with a Buy rating and announces Price Target of $10.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment